The news at a glance

Drug safety: A two-pronged attack on Avandia; Airlines: Southwest’s ambitious acquisition; Mergers: Unilever lassoes Alberto-Culver; Bankruptcies: Blockbuster throws in the towel; Departures: Geoghagen out at HSBC

Drug safety: A two-pronged attack on Avandia

“In a highly unusual coordinated announcement,” U.S. and European drug regulators sharply limited sales of Avandia, a diabetes drug that has been linked to strokes and heart attacks in patients, said Gardiner Harris in The New York Times. Sales of Avandia, made by GlaxoSmithKline, have been suspended entirely in Europe; patients in the U.S. can obtain Avandia only after providing a sworn statement that they’ve tried every other diabetes medicine and have been warned “of the drug’s substantial risks to the heart.” An estimated 47,000 Avandia users from 1999 through 2009 “needlessly suffered a heart attack, stroke, or heart failure, or died.” The company has taken a $2.3 billion charge against earnings to cover potential liability stemming from the drug’s side effects.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us